Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | December 03, 2021 | December 08, 2021 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | December 03, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 107,807 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 107,807 · Balance 107,807 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,819 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 9,819 · Balance 9,819 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,373 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 7,373 · Balance 7,373 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 80,324 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 80,324 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein.
Emergent BioSolutions Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,018,644 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 3,018,644 · Balance 3,018,644 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 274,930 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 274,930 · Balance 274,930 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 206,434 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 206,434 · Balance 206,434 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,136,971 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,136,971 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Unit · Derivative | 6,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · derivative · entry 10 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,774 Underlying: Common Stock · 6,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F8 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F8 · derivative.expiration_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 13,619 | $58.70 | $799,435.30 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,943 F3 · kind: All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.38 to $60.39. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,530 | $59.91 | $151,572.30 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,486,562 Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,489,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 01:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,365 | $59.91 | $141,687.15 |
DisclosureSEC source: 0000899243-20-006361 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,663 F1 · price: Represents a withholding of shares by Emergent Biosolutions Inc. to satisfy tax withholding obligations on the vesting of restricted stock units pursuant to award granted February 26, 2019, which was inadvertently not reported on a Form 4 filed on February 27, 2020. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Unit · Derivative | 6,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006083 · doc4.xml · derivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,203 Underlying: Common Stock · 6,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F6 · derivative.expiration_date: On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantRestricted Stock Unit · Derivative | 19,532 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006083 · doc4.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,213 Underlying: Common Stock · 19,532 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 25, 2020, Mr. El-Hibri was granted restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F5 · derivative.expiration_date: On February 25, 2020, Mr. El-Hibri was granted restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 39,061 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0000899243-20-006083 · doc4.xml · derivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,061 Underlying: Common Stock · 39,061 shares Expires 2027-02-24 F4 · derivative.exercise_date: On February 25, 2020, Mr. El-Hibri was granted 39,061 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-006083 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,485,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 18,567 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,567 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 18,567 | $64.90 | $1,204,998.30 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 18,567 | $25.62 | $475,686.54 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,497,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 4,751 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,567 Underlying: Common Stock · 4,751 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,751 | $64.90 | $308,339.90 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 01:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 4,751 | $25.62 | $121,720.62 |
DisclosureSEC source: 0000899243-20-005665 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 15,614 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,318 Underlying: Common Stock · 15,614 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,614 | $63.90 | $997,734.60 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 15,614 | $25.62 | $400,030.68 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,494,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 4,386 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,932 Underlying: Common Stock · 4,386 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,386 | $63.90 | $280,265.40 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:00 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 4,386 | $25.62 | $112,369.32 |
DisclosureSEC source: 0000899243-20-005195 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 13,720 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,318 Underlying: Common Stock · 13,720 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 13,720 | $62.90 | $862,988.00 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 13,720 | $25.62 | $351,506.40 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,492,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 6,280 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,038 Underlying: Common Stock · 6,280 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,280 | $62.90 | $395,012.00 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,280 | $25.62 | $160,893.60 |
DisclosureSEC source: 0000899243-20-004522 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,485,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 11,684 | $61.90 | $723,239.60 |
DisclosureSEC source: 0000899243-20-003714 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419,018 Read SEC document |
| February 06, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 11,684 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,318 Underlying: Common Stock · 11,684 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 06, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 11,684 | $25.62 | $299,344.08 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F3 · balance_after: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sale of Common Stock by the Reporting Person as reported on the Form 4 filed by the Reporting Person with the SEC on February 7, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 48,316 | $60.66 | $2,930,848.56 |
DisclosureSEC source: 0000899243-20-003714 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430,702 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $61.90. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 8,316 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,002 Underlying: Common Stock · 8,316 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · derivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,318 Underlying: Common Stock · 20,000 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,318 Underlying: Common Stock · 20,000 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F4 · derivative.exercise_date: The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 8,316 | $25.62 | $213,055.92 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F3 · balance_after: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sale of Common Stock by the Reporting Person as reported on the Form 4 filed by the Reporting Person with the SEC on February 7, 2020. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $25.62 | $512,400.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,519,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. Read SEC document |
| February 05, 2020 Filed Feb 13, 2020 23:33 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $25.62 | $512,400.00 |
DisclosureSEC source: 0000899243-20-004524 · doc4a.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on February 7, 2020, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 01:46 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 100,000 | $0.76 | $75,520.00 |
DisclosureSEC source: 0001019056-19-000476 · elhibri.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,536 F1 · kind: The transaction reported on this Form 4 was made by the Reporting Person pursuant to a trading plan adopted on May 31, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4999 to $0.8000 per share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 22:49 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 55,015 | $0.83 | $45,860.50 |
DisclosureSEC source: 0001593968-19-001685 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,536 F1 · price: The purchase price of $0.8336 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.81 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:49 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 10,000 | $0.90 | $8,996.00 |
DisclosureSEC source: 0001593968-19-001652 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,521 F1 · price: The purchase price of $0.8996 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.89 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 20:19 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 30,000 | $0.89 | $26,601.00 |
DisclosureSEC source: 0001593968-19-001649 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,521 F1 · price: The purchase price of $0.8867 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 19, 2019 Filed Jul 19, 2019 22:18 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 26,460 | $0.90 | $23,739.91 |
DisclosureSEC source: 0001593968-19-001645 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 929,521 F1 · price: The purchase price of $0.8972 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 21:12 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 14,404 | $0.87 | $12,596.30 |
DisclosureSEC source: 0001593968-19-001642 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,061 F1 · price: The purchase price of $0.8745 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.89. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 19,136 | $0.87 | $16,703.81 |
DisclosureSEC source: 0001593968-19-001640 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,657 F1 · price: The purchase price of $0.8729 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.88. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 16, 2019 Filed Jul 16, 2019 21:54 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 11,375 | $0.85 | $9,661.93 |
DisclosureSEC source: 0001593968-19-001632 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,521 F1 · price: The purchase price of $0.8494 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 16:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 14,691 | $0.85 | $12,453.56 |
DisclosureSEC source: 0001593968-19-001618 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858,146 F1 · price: The purchase price of $0.8477 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 20:10 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 18,919 | $0.85 | $16,058.45 |
DisclosureSEC source: 0001019056-19-000402 · elhibri.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,455 F1 · price: The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.845 to $0.85 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 17:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001278 · primary_01.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Units · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 16 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,681 Underlying: Common Stock · 9,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F12 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F12 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.